Winslow Evans & Crocker’s CRISPR Therapeutics CRSP Stock Holding History

Winslow Evans & Crocker’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$183K	Buy	1,195 +70	+6%	+$8.27K	0.03%	345
2020 Q3	$94K	Hold	1,125	–	–	0.02%	365
2020 Q2	$83K	Sell	1,125 -1	-0.1%	-$58	0.02%	383
2020 Q1	$48K	Buy	1,126 +524	+87%	+$27.1K	0.02%	430
2019 Q4	$38K	Hold	602	–	–	0.01%	545
2019 Q3	$26K	Buy	602 +102	+20%	+$4.87K	0.01%	610
2019 Q2	$24K	Hold	500	–	–	0.01%	637
2019 Q1	$18K	Hold	500	–	–	0.01%	684
2018 Q4	$16K	Hold	500	–	–	0.01%	660
2018 Q3	$24K	Hold	500	–	–	0.01%	623
2018 Q2	$30K	Buy	+500	New	+$28.5K	0.01%	596

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Winslow Evans & Crocker's CRSP Position: Q4 2020 in Review

Winslow Evans & Crocker increased its CRISPR Therapeutics (CRSP) stake by 6.2% in Q4 2020, buying an estimated $8.27K and bringing the position to 1,195 shares worth $183K. The position accounts for 0.03% of the portfolio, ranked #345.

Winslow Evans & Crocker first reported a position in CRSP in Q2 2018 and has held it in 11 quarters since. 412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

Winslow Evans & Crocker held 1,195 shares of CRISPR Therapeutics worth $183K as of Q4 2020.
Winslow Evans & Crocker bought 70 CRISPR Therapeutics shares in Q4 2020, an estimated $8.27K.
CRISPR Therapeutics made up 0.03% of Winslow Evans & Crocker's portfolio in Q4 2020, its #345 holding.
Winslow Evans & Crocker first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 11 quarters since.
412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.